SCHEMBL205265

SCHEMBL205265

CC1CN(C(=O)CCC(=O)NC2CCC(Cc3ccc(Cl)cc3)(N(C)C)CC2)CC(C)O1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 4/20 0.42
KDM4E B2RXH2 1/20 0.41
SSTR1 P30872 1/20 0.41
SSTR4 P31391 1/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.40
HSD11B1 P28845 1/20 0.39
HPGD P15428 2/20 0.39
CYP2C19 P33261 1/20 0.39
KCNH2 Q12809 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GLA P06280 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208277 0.87 SMN1; SMN2 (0.47) KMT2AL3MBTL1POLBSSTR1SSTR4
SCHEMBL209269 0.84 LMNA (0.41) KMT2APOLBSSTR1SSTR4ALDH1A1
SCHEMBL205723 0.83 ALDH1A1 (0.45) KMT2APOLBKDM4EALDH1A1LMNA
SCHEMBL206987 0.83 POLB (0.56) KMT2APOLBLMNAHPGDCYP2C19
SCHEMBL205853 0.82 HPGD (0.40) KMT2APOLBSSTR1SSTR4ALDH1A1
SCHEMBL207812 0.80 MAPT (0.48) KMT2APOLBALDH1A1LMNASMN1; SMN2
SCHEMBL206991 0.79 EPHX2 (0.43) KMT2APOLBSSTR1SSTR4ALDH1A1
SCHEMBL206876 0.79 MGLL (0.43) KMT2AL3MBTL1POLBKDM4EALDH1A1
SCHEMBL4072326 0.78 SIGMAR1 (0.49) KMT2ALMNAMEN1
SCHEMBL206115 0.77 NPC1 (0.38) KMT2ASSTR1SSTR4ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD KMT2A 3604/4885L3MBTL1 4705/4885POLB 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.